Symptom Perception
Primary Purpose
Asthma
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PEF Feedback
Asthma education
Sponsored by
About this trial
This is an interventional health services research trial for Asthma focused on measuring Older adults, Asthma, Symptom perception, Self-management behaviors, Medication adherence
Eligibility Criteria
Inclusion Criteria:
- Age ≥60 years
- English or Spanish speaking
- Asthma diagnosis made by a health care provider
Exclusion Criteria:
- Diagnosis of dementia
- Diagnosis of chronic obstructive pulmonary disease (COPD) or other chronic respiratory illness
- Smoking history of ≥15 pack-years owing to possible undiagnosed COPD
- Moderate or severe cardiac disease (including New York Heart Association stages 4 or 5 congestive heart failure, because dyspnea among patients with severe heart failure is more likely to be attributable to their heart condition than their asthma)
- Dependence on assistance for medication administration
- Uncorrectable visual impairment
Sites / Locations
- Albert Einstein College of Medicine/Yeshiva University
- Jacobi Medical Center
- Icahn School of Medicine at Mount Sinai
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Asthma education and PEF feedback
Asthma education
Arm Description
Patients receive asthma education and personal Peak expiratory flow (PEF) feedback
No PEF feedback arm
Outcomes
Primary Outcome Measures
Asthma Control Questionnaire (ACQ)
Change in self-reported asthma control validated survey, with a total score range from 0-6, with a higher score indicating severely uncontrolled asthma , used to assess current asthma control at pre-intervention, 1week post-pilot follow up visit and 4 weeks post-pilot follow-up visit
Change in Asthma Quality of Life Questionnaire (AQLQ)
Change in self-reported asthma-related quality of life validated survey used to assess asthma-related quality of life at at pre-intervention, 1week post-pilot follow up visit and 4 weeks post-pilot follow-up visit. Total Score from 1-7, with higher score indicating better quality of life.
Secondary Outcome Measures
Change in Medication Adherence Rating Scale (MARS)
MARS is a self-reported questionnaire with the total score range from 0-10 with a higher score indicating better adherence.
Change in Beliefs About Medicines Questionnaire (BMQ) - Necessity Score and Concerns Score
10-item scale that measures beliefs about asthma controller medication in 2 subdomains: necessity and concerns. All items have a five-point Likert answer option, ranging from 1 = strongly disagree to 5 = strongly agree, with total range from 10 to 50, with higher scores indicate stronger beliefs about the corresponding concepts.
Change in Beliefs About Illness Perception Questionnaire (BIPQ)
The BIPQ includes 9 items designed to rapidly assess the cognitive and emotional representations of illness- consequences, timeline, personal control, treatment control, experience symptoms, concerns, emotions and comprehensibility. For analyses, the first 8 items are summed and item 9 which is part of the causal scale is excluded. Items for personal control, treatment control and comprehensibility were reverse coded. All of the 8 items, are rated using a 0 (none) to 10 (extreme) response scale giving a sum total score of 0-80. Higher total scores indicate worse asthma perception.
Symptom Perception Measures Adjusted
Assessed based on alignment of patient guesses and actual PEF values recorded by the AM2 device and then categorizing into accurate, under or over-perception, adjusted for age, sex, race, monthly income Assesses if training and feedback can improve under perception of airflow obstruction and lead to better control in older adults with asthma
Asthma Control Questionnaire (ACQ) Score - Adjusted
Change in self-reported asthma control validated survey, with a total score range from 0-6, with a higher score indicating severely uncontrolled asthma, used to assess current asthma control at pre-intervention, 1week post-pilot follow up visit and 4 weeks post-pilot follow-up visit adjusted for age, sex, race, monthly income
Treatment Credibility
Treatment Credibility adjusted for age, sex, race, monthly income
The credibility of a treatment rationale consists of "how believable, convincing, and logical the treatment is". The CEQ credibility factor, reflecting a cognitively-based process, is based on patients' summed responses to three items measuring how logical the therapy seems, how successful one thinks it will be in reducing symptoms, and how confident one would be in recommending it to a friend with similar symptoms. The modified version used in this study included items rated on 7 point scales ranging from 1 (Not at all logical/successful /confident) to 7 (Very logical/successful /confident), with a total score possible range of 3 to 21. Higher scores indicate higher treatment credibility.
Treatment Expectancy
Treatment Expectancy adjusted for age, sex, race, monthly income.
Outcome expectancy consists of patients' beliefs about how likely they are to benefit from a treatment.
The CEQ expectancy factor, reflecting an affectively-based process, is based on patients' responses to three items reflecting how much they think they will improve by the end of treatment, how much they feel therapy will help reduce their symptoms, and how much they feel they will improve by the end of treatment. Because one item is on the same 7-point scale as the credibility items and two are assessed on an 11-point scale (from 0% to 100% in 10-point increments), responses are first standardized before summing to render the expectancy total score. The total score possible range is 3 to 33. Higher scores indicate higher treatment expectancy.
Change in Medication Adherence Rating Scale (MARS) Adjusted
MARS is a self-reported questionnaire with the total score range from 0-10 with a higher score indicating better adherence. MARS, adjusted for age, sex, race, monthly income
Full Information
NCT ID
NCT03646669
First Posted
August 22, 2018
Last Updated
May 4, 2023
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Albert Einstein College of Medicine, Jacobi Medical Center, National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT03646669
Brief Title
Symptom Perception
Official Title
Symptom Perception, Behavior, and Outcomes in Older Asthmatics
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
February 15, 2019 (Actual)
Primary Completion Date
April 1, 2022 (Actual)
Study Completion Date
April 1, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Albert Einstein College of Medicine, Jacobi Medical Center, National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Older asthmatics have considerably worse outcomes than younger patients with asthma. In this study, the investigators will evaluate the role of symptom perception as a key determinant of poorer outcomes and lower adherence to asthma self-management behaviors among older asthmatics. The proposed study is significant for its potential to greatly advance understanding of the mechanisms related to worse outcomes in older adults, and it will provide actionable data for new interventions to improve self-management.
Detailed Description
Asthma is a common condition in the older population and associated with worse morbidity and mortality compared to younger individuals. Various self-management behaviors (SMB), medication adherence in particular, are key for achieving good asthma control. Unfortunately, less than half of older asthmatics regularly adhere to their controller medications and to other SMB. Several observations suggest that symptom perception may be a major determinant of asthma SMB and outcomes in older adults. First, experimental studies consistently demonstrate that many older adults are substantially less aware of their level of airway obstruction. Second, under-perception of asthma symptoms is linked to elevated risk of near-fatal and fatal asthma attacks and increased morbidity among younger adults. Third, cognitive impairment, commonly associated with aging, has been identified as a key determinant of under-perception of symptoms in younger asthmatics. Fourth, interventions to correct symptom under-perception in children have been shown to improve asthma medication adherence. Despite the greater vulnerability of older asthmatics to poor asthma outcomes and their diminished ability to perceive the severity of their airway obstruction, the association of symptom perception with asthma SMB and outcomes has not been studied in this population. The goal of this project is to determine how symptom perception influences the management and outcomes of older asthmatics and to pilot test an intervention to correct under-perception. The Specific Aims are: 1) Prospectively assess the association between symptom perception and asthma morbidity among older adults; 2) Examine the association between symptom perception and asthma SMB among older adults and identify the pathways (via illness and medication beliefs) linking them; 3) Determine the influence of cognition on symptom perception among older adults with asthma; 4) Pilot test an intervention to correct under-perceptions of asthma symptoms in older adults. The investigators will conduct a prospective cohort study of 400 asthmatics ≥60 years of age recruited from East Harlem and the Bronx in New York City. The investigators will measure symptom perception in naturalistic settings using an innovative and validated methodology and repeatedly collect data on illness and medication beliefs, cognitive functioning, SMB (including objective measures of medication adherence), and asthma morbidity over 12 months. At the end of the observation period, the investigators will pilot test an intervention to improve symptom perception on a random sample of 80 participants. The proposed study is significant for its potential to greatly advance understanding of the mechanisms related to low adherence to SMB and worse outcomes in older asthmatics, a vulnerable and understudied population.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Older adults, Asthma, Symptom perception, Self-management behaviors, Medication adherence
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
58 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Asthma education and PEF feedback
Arm Type
Experimental
Arm Description
Patients receive asthma education and personal Peak expiratory flow (PEF) feedback
Arm Title
Asthma education
Arm Type
Placebo Comparator
Arm Description
No PEF feedback arm
Intervention Type
Behavioral
Intervention Name(s)
PEF Feedback
Other Intervention Name(s)
Intervention Arm
Intervention Description
Patients in the PEF feedback arm will receive a one-time session including asthma management education, discussion of their asthma symptoms, review of individual PEF results and perception of symptoms, and problem-solving techniques to improve asthma self-management. After the session, the participants in this arm will be able to view in the display of the AM2 device their PEF values and will be instructed to mentally note their actual results with their pre-effort estimated BPF. They will also set a motivational message for themselves that will appear on the device.
Intervention Type
Behavioral
Intervention Name(s)
Asthma education
Intervention Description
General asthma education, AM2 training, and positive counseling, but no discussion linking asthma symptom perception to SMB. Following the session, these participants will use the AM2 to track PEF actual and perceived values twice per day, but they will be blinded to the actual PEF values. Control arm patients will see a standard motivational message appear on the screen of the AM2 device.
Primary Outcome Measure Information:
Title
Asthma Control Questionnaire (ACQ)
Description
Change in self-reported asthma control validated survey, with a total score range from 0-6, with a higher score indicating severely uncontrolled asthma , used to assess current asthma control at pre-intervention, 1week post-pilot follow up visit and 4 weeks post-pilot follow-up visit
Time Frame
Baseline, 1 week follow up, 1 month follow up
Title
Change in Asthma Quality of Life Questionnaire (AQLQ)
Description
Change in self-reported asthma-related quality of life validated survey used to assess asthma-related quality of life at at pre-intervention, 1week post-pilot follow up visit and 4 weeks post-pilot follow-up visit. Total Score from 1-7, with higher score indicating better quality of life.
Time Frame
Baseline, 1 week follow up, 1 month follow up
Secondary Outcome Measure Information:
Title
Change in Medication Adherence Rating Scale (MARS)
Description
MARS is a self-reported questionnaire with the total score range from 0-10 with a higher score indicating better adherence.
Time Frame
Baseline, 1 week follow up, 1 month follow up
Title
Change in Beliefs About Medicines Questionnaire (BMQ) - Necessity Score and Concerns Score
Description
10-item scale that measures beliefs about asthma controller medication in 2 subdomains: necessity and concerns. All items have a five-point Likert answer option, ranging from 1 = strongly disagree to 5 = strongly agree, with total range from 10 to 50, with higher scores indicate stronger beliefs about the corresponding concepts.
Time Frame
Baseline, 1 week follow up, 1 month follow up
Title
Change in Beliefs About Illness Perception Questionnaire (BIPQ)
Description
The BIPQ includes 9 items designed to rapidly assess the cognitive and emotional representations of illness- consequences, timeline, personal control, treatment control, experience symptoms, concerns, emotions and comprehensibility. For analyses, the first 8 items are summed and item 9 which is part of the causal scale is excluded. Items for personal control, treatment control and comprehensibility were reverse coded. All of the 8 items, are rated using a 0 (none) to 10 (extreme) response scale giving a sum total score of 0-80. Higher total scores indicate worse asthma perception.
Time Frame
Baseline, 1 week follow up
Title
Symptom Perception Measures Adjusted
Description
Assessed based on alignment of patient guesses and actual PEF values recorded by the AM2 device and then categorizing into accurate, under or over-perception, adjusted for age, sex, race, monthly income Assesses if training and feedback can improve under perception of airflow obstruction and lead to better control in older adults with asthma
Time Frame
Baseline, 1 week follow up, 1 month follow up
Title
Asthma Control Questionnaire (ACQ) Score - Adjusted
Description
Change in self-reported asthma control validated survey, with a total score range from 0-6, with a higher score indicating severely uncontrolled asthma, used to assess current asthma control at pre-intervention, 1week post-pilot follow up visit and 4 weeks post-pilot follow-up visit adjusted for age, sex, race, monthly income
Time Frame
Baseline, 1 week follow up, 1 month follow up
Title
Treatment Credibility
Description
Treatment Credibility adjusted for age, sex, race, monthly income
The credibility of a treatment rationale consists of "how believable, convincing, and logical the treatment is". The CEQ credibility factor, reflecting a cognitively-based process, is based on patients' summed responses to three items measuring how logical the therapy seems, how successful one thinks it will be in reducing symptoms, and how confident one would be in recommending it to a friend with similar symptoms. The modified version used in this study included items rated on 7 point scales ranging from 1 (Not at all logical/successful /confident) to 7 (Very logical/successful /confident), with a total score possible range of 3 to 21. Higher scores indicate higher treatment credibility.
Time Frame
1 week follow up, 1 month follow up
Title
Treatment Expectancy
Description
Treatment Expectancy adjusted for age, sex, race, monthly income.
Outcome expectancy consists of patients' beliefs about how likely they are to benefit from a treatment.
The CEQ expectancy factor, reflecting an affectively-based process, is based on patients' responses to three items reflecting how much they think they will improve by the end of treatment, how much they feel therapy will help reduce their symptoms, and how much they feel they will improve by the end of treatment. Because one item is on the same 7-point scale as the credibility items and two are assessed on an 11-point scale (from 0% to 100% in 10-point increments), responses are first standardized before summing to render the expectancy total score. The total score possible range is 3 to 33. Higher scores indicate higher treatment expectancy.
Time Frame
1 week follow up, 1 month follow up
Title
Change in Medication Adherence Rating Scale (MARS) Adjusted
Description
MARS is a self-reported questionnaire with the total score range from 0-10 with a higher score indicating better adherence. MARS, adjusted for age, sex, race, monthly income
Time Frame
Baseline, 1 week follow up, 1 month follow up
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥60 years
English or Spanish speaking
Asthma diagnosis made by a health care provider
Exclusion Criteria:
Diagnosis of dementia
Diagnosis of chronic obstructive pulmonary disease (COPD) or other chronic respiratory illness
Smoking history of ≥15 pack-years owing to possible undiagnosed COPD
Moderate or severe cardiac disease (including New York Heart Association stages 4 or 5 congestive heart failure, because dyspnea among patients with severe heart failure is more likely to be attributable to their heart condition than their asthma)
Dependence on assistance for medication administration
Uncorrectable visual impairment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Juan Wisnivesky, MD, MPH
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Albert Einstein College of Medicine/Yeshiva University
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Name
Jacobi Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Symptom Perception
We'll reach out to this number within 24 hrs